Want to see HK:6667 full AI Analyst Report?
6667 Stock Chart & Stats
HK$7.28
-HK$0.11(-1.16%)
At close: 4:00 PM EST
HK$7.28
-HK$0.11(-1.16%)
Day’s Range― - ―
52-Week RangeHK$4.80 - HK$7.53
Previous CloseN/A
Volume152.60K
Average Volume (3M)42.47K
Market Cap
HK$1.59B
Enterprise ValueHK$995.76
Total Cash (Recent Filing)HK$424.49M
Total Debt (Recent Filing)HK$28.52M
Price to Earnings (P/E)50.1
Beta0.06
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.44%
Share Statistics
EPS (TTM)0.12
Shares Outstanding224,300,200
10 Day Avg. Volume108,240
30 Day Avg. Volume42,473
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)2.09
Price to Sales (P/S)5.17
P/FCF Ratio-76.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a substantial equity base provide financial resilience and flexibility. This structure can help the company withstand operating volatility, fund initiatives without excessive borrowing, and preserve strategic options over the next several quarters.
Strong Recent Revenue GrowthRapid recent revenue expansion indicates improving commercial scale and demand relative to the prior year. If maintained, a larger revenue base can support operating leverage, broaden market reach, and provide more resources for continued business development.
Historical Cash-generation CapabilityAlthough the latest year was weak, prior substantial operating cash generation shows the business has produced cash under more favorable conditions. That historical capability provides a foundation for recovery if cash conversion stabilizes and supports internally funded growth.
Bears Say
Negative Latest-year Cash FlowNegative operating and free cash flow despite accounting profit signals weak recent cash conversion. Persistent outflows could reduce internally available funding, increase reliance on the strong balance sheet, and constrain investment or shareholder-return capacity.
Margin And Earnings CompressionMaterial margin contraction means additional revenue is currently producing less profit than in earlier peak years. The decline in net income despite higher sales raises concerns about earnings quality and limits the durability of reported top-line growth.
Low Returns And Earnings CyclicalityModest returns on a large equity base indicate that capital is not currently generating strong profitability. Combined with the prior annual loss, this points to earnings cyclicality that may make results less predictable and weaken compounding potential.
Mega Genomics Limited News
6667 FAQ
What was Mega Genomics Limited’s price range in the past 12 months?
Mega Genomics Limited lowest stock price was HK$4.80 and its highest was HK$7.53 in the past 12 months.
What is Mega Genomics Limited’s market cap?
Mega Genomics Limited’s market cap is HK$1.59B.
When is Mega Genomics Limited’s upcoming earnings report date?
Mega Genomics Limited’s upcoming earnings report date is Apr 01, 2027 which is in 187 days.
How were Mega Genomics Limited’s earnings last quarter?
Mega Genomics Limited released its earnings results on Aug 31, 2026. The company reported HK$0.138 earnings per share for the quarter.
Is Mega Genomics Limited overvalued?
According to Wall Street analysts Mega Genomics Limited’s price is currently Overvalued.
Does Mega Genomics Limited pay dividends?
Mega Genomics Limited pays a Notavailable dividend of HK$0.17 which represents an annual dividend yield of 2.44%. See more information on Mega Genomics Limited dividends here
What is Mega Genomics Limited’s EPS estimate?
Mega Genomics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mega Genomics Limited have?
Mega Genomics Limited has 224,300,200 shares outstanding.
What happened to Mega Genomics Limited’s price movement after its last earnings report?
Mega Genomics Limited reported an EPS of HK$0.138 in its last earnings report. Following the earnings report the stock price went down -0.07%.
Which hedge fund is a major shareholder of Mega Genomics Limited?
Currently, no hedge funds are holding shares in HK:6667
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mega Genomics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.95%
12-Months-Change
Fundamentals
Return on Equity
2.44%
Trailing 12-Months
Asset Growth
27.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mega Genomics Limited
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.
Technical Analysis
Acotec Scientific Holdings Limited
―
Kindstar Globalgene Technology, Inc.
―
IVD Medical Holding Limited
―
WuXi AppTec Co., Ltd. Class H
―
Hangzhou Jiuyuan Gene Engineering Co Ltd Class H
―